YOLFTbeta
Changchun BCHT Biotechnology Co. A

Changchun BCHT Biotechnology Co. A

688276 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

15.45CNY-0.56 (-3.50%)

Price History

Full chart

Market Stats

Previous Close16.01
Open16.00
Day Range15.40 – 16.00
52-Week Range13.30 – 24.47
Volume1.99M
Market Cap7.43B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.59
Dividend Yield0.00%
Beta0.04
50-Day Avg16.03
200-Day Avg17.34

About

Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. It offers therapeutic biological products; general cargo road transport; special cargo transport and import and export of goods and technology. The company's products Varicella vaccine, nasal spray flu vaccine, herpes zoster vaccine, liquid nasal spray flu vaccine. Changchun BCHT Biotechnology Co. Ltd. was founded in 2004 and is based in Changchun, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Chunlai Jiang
  • Employees1.23K
  • HeadquartersNo. 1260 Huoju Road, Changchun, China, China
  • Websitehttps://www.bchtpharm.com

Leadership

  • Mr. Chunlai JiangGM & Director · b. 1973
  • Mr. Zhaofeng MengChief Financial Officer · b. 1964
  • Mr. Zhe ZhangBoard Secretary · b. 1976
  • Mr. Dawei LiuDeputy General Manager · b. 1972
  • Ms. Wei WeiDeputy General Manager · b. 1970
  • Mr. Changlin ZhuSecretary of the Party Branch, Chairman of the Trade Union, & Chief Engineer of BaiKe Biotechnology · b. 1969
  • Zang YangExecutive Vice President of the Institute of Drug Research

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue690.62M1.02B975.67M1.44B1.20B1.07B1.82B1.23B591.81M
Growth (%)-+47.54%-4.24%+47.73%-16.60%-10.86%+70.30%-32.64%-51.85%
Cost of Revenue76.27M118.80M102.74M176.27M228.56M181.93M210.35M206.06M160.74M
Gross Profit614.35M900.12M872.93M1.27B973.47M889.52M1.61B1.02B591.81M
Gross Margin88.96%88.34%89.47%87.77%80.99%83.02%88.47%83.23%100.00%
Operating Expense500.25M750.69M605.05M782.92M711.56M702.60M1.06B765.13M954.37M
Operating Income114.09M149.43M267.88M482.17M261.90M186.92M559.29M257.89M-362.56M
Operating Margin16.52%14.67%27.46%33.45%21.79%17.45%30.65%20.98%-61.26%
EBITDA139.86M191.14M315.02M549.73M330.40M268.78M656.61M361.65M-239.01M
EBITDA Margin20.25%18.76%32.29%38.14%27.49%25.09%35.98%29.42%-40.39%
Net Income93.48M128.06M221.02M418.23M243.55M181.54M501.01M232.09M-272.07M
Net Income Margin13.54%12.57%22.65%29.02%20.26%16.94%27.46%18.88%-45.97%
R&D41.04M61.80M65.16M93.36M156.76M133.53M198.07M188.38M177.10M
R&D as % of Total Revenue5.94%6.07%6.68%6.48%13.04%12.46%10.86%15.33%29.93%
Interest Expense11.44M9.53M8.42M4.22M494.91K146.31K868.14K1.70M3.90M
Interest Expense % of Total Revenue1.66%0.94%0.86%0.29%0.04%0.01%0.05%0.14%0.66%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.14B1.41B1.58B2.47B4.17B4.28B5.05B5.20B5.07B
Total Liabilities542.45M610.74M570.29M687.57M757.05M724.02M1.03B987.12M1.22B
Total Equity600.51M799.55M1.01B1.78B3.42B3.56B4.02B4.22B3.85B
Cash128.88M210.34M272.80M309.63M1.16B866.54M442.18M344.87M201.24M
Total Debt-165.00M165.00M---20.47M102.83M-
Net Debt-128.88M-45.34M-107.80M-309.63M-1.16B-866.54M-421.71M-242.04M43.53M

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow177.05M269.79M232.80M209.16M140.30M39.82M255.21M406.50M231.21M
Investing Cash Flow-101.87M-154.76M-128.39M-333.59M-695.51M-288.72M-638.63M-541.48M-
Financing Cash Flow-6.39M-38.47M-56.69M174.39M1.40B-41.28M-42.14M36.97M-
Capital Expenditure92.44M181.15M128.39M335.75M632.88M290.73M470.66M542.43M406.49M
Free Cash Flow84.61M88.64M104.40M-126.58M-492.58M-250.91M-278.07M-135.92M-175.28M
Dividends Paid2.39M18.47M8.30M4.05M328.77K41.28M62.61M64.39M75.03M
FCF to OCF47.79%32.86%44.85%-60.52%-351.09%-630.14%-108.96%-33.44%-75.81%
Dividend Paid to FCF2.83%20.84%7.95%-3.20%-0.07%-16.45%-22.52%-47.38%-42.81%

Earnings

Report DateAug 14, 2021Oct 29, 2021Feb 18, 2022Apr 27, 2022Aug 25, 2022Oct 27, 2022Mar 29, 2023Apr 17, 2023Oct 25, 2024Apr 20, 2025
EPS Estimate--------0.600.49
EPS Actual0.200.280.030.040.140.34-0.070.040.26-0.03
Surprise---------56.67%-106.12%
TimingAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hours

Key Statistics & Ratios

Market Cap7.43B
Enterprise Value7.73B
Trailing P/E0.00
Forward P/E0.00
Price / Sales11.89
Price / Book1.99
EPS-0.59
Book Value9.17
Revenue (TTM)624.69M
Gross Profit (TTM)408.29M
EBITDA-122.88M
Profit Margin-38.60%
Operating Margin-30.26%
Return on Equity-6.13%
Return on Assets-3.09%
Shares Outstanding413.66M
Shares Float121.27M
Beta0.04
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20251×
0.17Jun 18, 2025
20241×
0.15May 24, 2024
20231×
0.15Jun 12, 2023
20221×
0.10Jul 15, 2022